Ginger Webb, APRN
Nurse Practitioner · Pikeville, KYNPI 1770990061
Payments from drug & device makers
Across 583 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$685
- GSK$629
- Lilly USA, LLC$566
- Takeda Pharmaceuticals U.S.A., Inc.$480
- Amgen$458
- plus $5K from 29 others
What the payments were for
- Food & beverage$9,05399%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 113 | $1,774 |
| Pfizer | 47 | $685 |
| GSK | 39 | $629 |
| Lilly USA, LLC | 40 | $566 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $480 |
| Amgen | 26 | $458 |
| Novo Nordisk | 29 | $440 |
| Boehringer Ingelheim | 30 | $439 |
| Novartis | 34 | $422 |
| AstraZeneca | 21 | $395 |
| Merck | 24 | $381 |
| Bayer | 19 | $335 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $266 |
| Grifols USA, LLC | 11 | $211 |
| Kowa Pharmaceuticals America, Inc. | 11 | $173 |
| Johnson & Johnson | 18 | $161 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $152 |
| Sanofi-aventis U.S. LLC | 9 | $145 |
| Daiichi Sankyo Inc. | 9 | $144 |
| Biohaven Pharmaceuticals, Inc. | 9 | $142 |
| Redhill Biopharma Inc. | 8 | $114 |
| Exact Sciences | 5 | $87 |
| Amarin Pharma, Inc. | 7 | $84 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $67 |
| Phathom Pharmaceuticals, Inc. | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Optinose US, Inc. | 3 | $52 |
| Impel Pharmaceuticals Inc. | 3 | $44 |
| Verona Pharma, Inc. | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Ardelyx, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$9,118 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 79 | $100,934 |
| JardianceEmpagliflozin | 123 | $100,750 |
| TrulicityDulaglutide | 80 | $80,254 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $79,376 |
| FarxigaDapagliflozin Propanediol | 74 | $66,265 |
| OzempicSemaglutide | 54 | $54,462 |
| RybelsusSemaglutide | 26 | $33,891 |
| JanuviaSitagliptin Phosphate | 40 | $33,225 |
| VascepaIcosapent Ethyl | 64 | $31,206 |
| XareltoRivaroxaban | 25 | $20,073 |
| EliquisApixaban | 19 | $15,653 |
| MyrbetriqMirabegron | 22 | $15,605 |
| LinzessLinaclotide | 24 | $15,534 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $11,909 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $11,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $566 | $181,189159 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $439 | $111,532144 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $629 | $91,284123 claims |
| Novo NordiskOzempic, Rybelsus | $440 | $88,35380 claims |
| AstraZenecaFarxiga | $395 | $66,26574 claims |
| MerckJanuvia | $381 | $33,22540 claims |
| AbbVieLinzess, Creon, Lumigan | $1,774 | $25,57648 claims |
| Johnson & JohnsonXarelto | $161 | $20,07325 claims |
| PfizerEliquis | $685 | $15,65319 claims |
| Redhill Biopharma Inc.Movantik | $114 | $6,13215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in Pikeville
- Staci TaylorPikeville$11K
- Elizabeth BranhamPikeville$10K
- Kendra DrakePikeville$10K
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.